Commentary|Videos|November 19, 2026

Does Pimicotinib Expand Options in Tenosynovial Giant Cell Tumor?

Fact checked by: Melissa Venditti

FDA approval of pimicotinib adds another CSF1R inhibitor for tenosynovial giant cell tumor, says Andrew J. Wagner, MD, PhD, of Dana-Farber Cancer Institute.

Does Pimicotinib Expand Options in Tenosynovial Giant Cell Tumor?

The FDA has approved pimicotinib (Pimjetmi) for adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for whom surgical resection carries a high risk of severe morbidity or worsening functional limitation. Andrew J. Wagner, MD, PhD, of Dana-Farber Cancer Institute, said the agent joins pexidartinib (Turalio) and vimseltinib (Romvimza) in a class that has moved TGCT from a disease managed almost entirely with surgery to one treated with drug therapy.

Pimicotinib is a once-daily, orally administered, highly selective CSF-1R inhibitor, given at a recommended dose of 50 mg once daily. Approval was primarily based on the global phase 3 MANEUVER trial (NCT05804045), in which pimicotinib produced an overall objective response rate of 56% at week 25 vs 3.2% with placebo, alongside improved joint function and pain reduction. The agent was previously approved in China (December 2025), Canada (June 2026), and Switzerland (October 2026).

CSF1 Biology and the Shift to Drug Therapy

Wagner says the biggest change came 10 to 15 years ago, when colleagues at Stanford University discovered that these tumors are driven by overexpression of CSF1, which stimulates the CSF1 receptor on macrophages and histiocytes drawn to the joint. Those cells make up the bulk of the tumor. He calls the finding a paradigm shift from a disease managed almost purely with surgery. His team began using imatinib (Gleevec) off label because of its activity against the receptor, before more specific and potent agents were developed.

“They all have very similar activity,” Wagner says in the interview.

Choosing Among Agents

Wagner says the agents have slightly different dosing schedules and side effect profiles, so selection balances patient preferences for dosing and tolerance of specific adverse events. He said outcomes for tumor shrinkage and patient-reported outcomes are very similar across the agents.

Patient-Reported Outcomes as a Study Focus

Wagner says that when his group designed the studies, the focus was on how patients felt in response to treatment, because TGCT is not life-threatening for the vast majority of patients. Shrinking the tumor without improving how patients felt would not help them, he says, and improving symptoms without shrinking the tumor would amount to “a very expensive form of ibuprofen.”

“So we wanted both of those things to happen,” Wagner says.

Assessing Response in Practice

In the research studies, investigators used formal measurements of range of motion, pain, and physical function. In clinical practice, Wagner said, the assessment can be more direct: asking patients what they could not do before compared with what they can do today, how their symptoms are changing, and whether they think the treatment is helping. Those answers drive whether a drug is continued or therapy is changed.

REFERENCE
1. FDA approves pimicotinib for symptomatic tenosynovial giant cell tumor. FDA. Accessed November 17, 2026. https://tinyurl.com/thz9wb9w

Related to this article

FDA Removes PCNSL Limitation From Liso-Cel Label
The November 2026 prescribing information removes the limitation that previously excluded patients with primary or secondary central nervous system lymphoma from the therapy’s large B-cell lymphoma indications.